Nanotherapeutics in transplantation: How do we get to clinical implementation?

Patients undergoing organ transplantation transition from one life‐altering issue (organ dysfunction) to a lifelong commitment—immunosuppression. Regimens of immunosuppressive agents (ISAs) come with significant side effects and comorbidities. Recently, the use of nanoparticles (NPs) as a solution t...

Descripción completa

Detalles Bibliográficos
Autores principales: Plumblee, Leah, Atkinson, Carl, Jaishankar, Dinesh, Scott, Evan, Tietjen, Gregory T., Nadig, Satish N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081154/
https://www.ncbi.nlm.nih.gov/pubmed/35224837
http://dx.doi.org/10.1111/ajt.17012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081154/
https://www.ncbi.nlm.nih.gov/pubmed/35224837
http://dx.doi.org/10.1111/ajt.17012

Ejemplares similares